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ABSTRACT A new series of pyridazinone-based thioderivatives and pyridazine analogs was synthe-
sized and tested for their ability to bind to the three human formyl peptide receptor (FPR) isoforms (FPR1,
FPR2, and FPR3) and to activate intracellular calcium mobilization and chemotaxis in human neutrophils.
Among the pyridazin-3(2H)-one derivatives tested, analogs 8b and 8c were mixed FPR1/FPR2 agonists,
with median effective concentration values in the micromolar range, and were able to activate chemotaxis
and Ca2+ flux in human neutrophils in the low micromolar range. Molecular docking studies showed that
interaction of a ligand with Arg205 of FPR1 is important for FPR1 agonist activity. For FPR2, differences in
activity between oxygen-containing compounds and their thio-analogs were due to steric bulkiness of
sulfur-containing groups. Drug Dev Res 74 : 259–271, 2013. © 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Formyl peptide receptors (FPRs) are a family of
chemoattractant receptors that play an essential role in
host defense against infection and trauma. In addition,
they are involved at different levels in the regulation of
inflammatory reactions and sensing cellular dysfunction
[Migeotte et al., 2006]. FPRs belong to the seven trans-
membrane domain G-protein-coupled receptor family,
are expressed in the majority of white blood cells,
and are important in host defense and inflammation
[Ye et al., 2009]. All major neutrophil functions accom-
plished through FPRs can be inhibited by treatment
with pertussis toxin [Bokoch and Gilman, 1984], indi-
cating that the G proteins coupled to FPRs belong
to the Gi family of heterotrimeric proteins [Simon
et al., 1991]. Activation of FPRs induces a variety of
responses, e.g. directional movement of neutrophils,
lysosomal enzyme release [Schiffmann et al., 1975],
degranulation, and production of superoxide anion
[Prossnitz and Ye, 1997; Mills et al., 1999; Le et al.,
2002]. Three FPR subtypes have been identified in
humans (FPR1, FPR2, and FPR3) [Ye et al., 2009].
FPR1 was the first that was biochemically defined
and was a high-affinity binding site on the surface of
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neutrophils for the prototypic peptide formyl-
methionine-leucine-phenylalanine (fMLF) [Ye et al.,
2009]. FPR2 shares 69% amino acid identity with
human FPR1, but despite the relatively high level of
sequence homology, is a low-affinity receptor for fMLF
[Quehenberger et al., 1993]. FPR3 shares 56% and
83% sequence identity with human FPR1 and FPR2,
respectively, but does not bind N-formyl peptides, e.g.
fMLF. Instead, FPR3 responds to some nonformylated
chemotactic peptides identified as FPR2 agonists.
FPRs interact with a wide range of structurally
different pro- and anti-inflammatory ligands associated
with different diseases, including amyloidosis and
Alzheimer’s disease [Cui et al., 2002], some types of
cancers and related alopecia induced by most antican-
cer agents [Edwards et al., 2005; Tsuruky et al., 2007],
prion diseases [Zhou et al., 2009], HIV [Kilby et al.,
1998], stomach ulcers [De Paulis et al., 2004], and
nociception associated with inflammatory processes
[Pieretti et al., 2004]. Many studies indicate that FPRs
are important mediators of key events in endogenous
anti-inflammation, and it has been proposed that FPR
modulation is an attractive approach for the targeting
biochemical processes for resolving inflammation
[Gilroy et al., 2004]. Likewise, FPRs may represent
therapeutic targets for selectively stimulating innate
immune responses [Serhan et al., 2007; Zhang and
Falla, 2009; Dufton and Perretti, 2010].
Previous studies led to the identification of a wide
range of structurally unrelated nonpeptide and peptide
FPR agonists, including synthetic molecules and both
host-derived and pathogen-derived agents [Bokoch
et al., 1984; Gierschik et al., 1989], and more recently,
we identified a large number of potentFPRagonistswith
a pyridazin-3(2H)-one scaffold that contained a meth-
oxybenzyl group at position 4 [Cilibrizzi et al., 2009,
2012]. Two of the most interesting compounds of the
series are shown in Figure 1: compound 1 is a mixed
FPR1/FPR2 agonist with activity in the low micromolar
range (median effective concentration values [EC50] =
3.4 and 3.8 mM for FPR1 and FPR2, respectively),
whereas compound 2 is a FPR2-specific agonist (EC50 =
2.4 mM). Structural analysis of this series of compounds
indicated that an acetamide spacer atN-2 of the pyridazi-
none ring is an essential requirement for specificity and
potency of these compounds, and the role of both C = O
(H-bond acceptor) and amidic NH (H-bond donor) in
the side chain was crucial for binding to FPRs. More-
over, the presence of a lipophilic and/or electronegative
para substituent in the aromatic system of the side chain
at position 2 was an important element required for
potency and selectivity [Cilibrizzi et al., 2009].
Based on previous reports demonstrating benefi-
cial substitutions of C = S for C = O and methylthio
(SCH3) for methoxy (OCH3) [Wrobel et al., 1989;
Güngör et al., 2006], we designed a series of thio-analogs
characterized by properties similar to those of previously
reported parent compounds [Cilibrizzi et al., 2009].
Furthermore, a series of pyridazine analogs where the
phenylacetamide moiety was moved to position 3 of the
ring was also designed. For all new compounds, we
report herein the synthesis and biological evaluation for
FPR agonist activity, selectivity versus FPR1/FPR2/
FPR3, and the ability to activate intracellular calcium
mobilization and chemotaxis in human neutrophils.
MATERIALS AND METHODS
Chemistry
Syntheses of the new pyridazin-3(2H)-one and
pyridazine thioderivatives are depicted in Figures
2 and 3. In Figure 2, procedures to obtain the
pyridazinone-3(2H)-one thioderivatives 8a-c, 9 and
the thiopyridazine analog 11 are reported. In both
cases, the starting material was the 6-methyl-4,5-
dihydropyridazin-3(2H)-one compound 4 [Meng and
Hesse, 1990], which was directly converted in the new
benzyl derivative 5a and the previously described 5b,c
[Cilibrizzi et al., 2009] by Knoevenagel condensa-
tion using the appropriate aromatic aldehyde in the
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Fig. 1. Structures of selected FPRs agonists 1–3.
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presence of KOH in absolute EtOH (5% w/v). Alkyla-
tion of intermediates 5a, 5b with ethyl bromoacetate
resulted in the esters 6a, 6b, [Cilibrizzi et al., 2009],
which after alkaline hydrolysis gave the corresponding
acids 7a,b [Cilibrizzi et al., 2009]. Subsequent reaction
of 7a,b with ethyl chloroformate in THF in presence of
triethylamine resulted in the intermediate mixed anhy-
drides, which in turn were transformed in good yields
into the final amide 1 [Cilibrizzi et al., 2009] and the
new compounds 8a-c. Moreover, the thioamide analog
9 was directly generated from compound 1 by treat-
ment with Lawesson’s reagent in toluene at 80°C
[Jesberger et al., 2003]. Considering that compound 1
has two carbonyl groups susceptible to thionation, both
1H NMR and MS(ESI) analyses were performed to
confirm structure 9. MS analysis clearly demonstrated
the presence of a fragment of compound 9 containing
the pyridazinone nucleous, and 1H NMR experiments
showed a clear difference in the chemical shift of the
signal related to N-CH2-CO in 1 and the corresponding
N-CH2-CS in compound 9. These findings suggest that
the pyridazinone ring was unchanged, and the sulfur
was present only and univocally on the side chain.
Figure 2 also depicts the synthetic procedure for
obtaining the pyridazine analog 11. Using Lawesson’s
reagent, as described above, the precursor 5c [Cilibrizzi
et al., 2009] was transformed into the intermediate 10
which, in turn, was alkylated under standard conditions
with N-(4-bromophenyl)-2-chloroacetamide [Baraldi
et al., 2007] to obtain the final compound 11, contain-
ing the phenylacetamide moiety at C-3 of the ring.
The synthetic procedure to obtain pyridazine
analogs 15a,b and 18 is depicted in Figure 3. The
previously described 3-chloro-6-phenylpyridazin-4-ol,
compound 12 [Sircar, 1983] was converted into
intermediate 13 by performing a cross-coupling reac-
tion with the appropriate aryl boronic acids, using
copper acetate as catalyst and a weak base (triethy-
lamine) in CH2Cl2 [Quach and Batey, 2003; Chiang
and Olsson, 2004]. Compound 13 was then treated
with saturated ethanolic ammonia at 180°C to obtain
the corresponding 3-amino derivative 14, which
was directly reacted under standard conditions with
the 4-bromophenylisocyanate or the 4-bromobenzoyl
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Fig. 2. Synthesis of pyridazin-3(2H)-one-based thioderivatives 8a-c, 9 and pyridazine analog 11.
Reagents and conditions: (A) substituted benzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous EtOH, 1–5 h, reflux; (B) ethyl bromoacetate (1.5
equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2–4 h, reflux; (C) NaOH 6 N, 1–2 h, 80°C; (D) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv),
substituted aniline (2 equiv), anhydrous THF, 12 h, -5°C → rt; (E) Lawesson’s reagent (2 equiv), anhydrous toluene, 2–3 h, 80°C; (F)
N-(4-bromophenyl)-2-chloroacetamide (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 3 h, reflux.
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chloride to obtain the urea 15a and the amide 15b,
respectively. Alternatively, final compound 18 was pre-
pared from intermediate 14 by performing the same
reaction sequence (alkylation with ethyl bromoacetate,
alkaline hydrolysis, and finally, through the intermedi-
ate mixed anhydride, coupling with 4-bromoaniline)
shown in Figure 2 for compounds 1 and 8a-c.
Experimental
All chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Extracts were dried over
Na2SO4, and the solvents were removed under reduced
pressure. All reactions were monitored by thin layer
chromatography (TLC) using commercial plates pre-
coated with Merck silica gel 60 F-254 (Merck, Darms-
tadt, Germany). Visualization was performed by UV
fluorescence (lmax = 254 nm) or by staining with iodine
or potassium permanganate. Chromatographic separa-
tions were performed on a silica gel column by gra-
vity chromatography (Kieselgel 40, 0.063–0.200 mm;
Merck) or flash chromatography (Kieselgel 40, 0.040–
0.063 mm; Merck). All melting points were determined
on a microscope hot stage Büchi apparatus (Assago,
Milano, Italy) and are uncorrected. Yields refer to
chromatographically and spectroscopically pure com-
pounds, unless otherwise stated. The identity and purity
of intermediates and final compounds were ascertained
through 1H NMR and TLC. 1H NMR spectra were
recorded with Avance 400 instruments (Bruker Biospin
Version 002, Bruker AXS Inc., Madison, WI USA with
full digital signal generation [SGU]). Chemical shifts (d)
were reported in ppm to the nearest 0.01 ppm, using
the solvent as the internal standard. Coupling constants
(J-values) are given in Hz and were calculated using
TopSpin 1.3 software (Bruker) rounded to the nearest
0.1 Hz. Mass spectra (m/z) were recorded on an
ESI-MS triple quadrupole mass spectrometer (Varian
1200L, Sunnyvale, CA USA). Microanalyses were per-
formed with a Perkin-Elmer 260 elemental analyzer
(Waltham, MA USA) for C, H, and N, and the results
were within  0.4% of the theoretical values, unless
otherwise stated.
General procedure for compounds (5a-c)
To 12 ml of a solution of KOH in absolute EtOH
(5%, w/v), compound 4 (4.46 mmol) and the appropri-
ate aromatic aldehyde (4.46 mmol) were added, and the
solution was refluxed under stirring for 1–5 h. After
cooling, the mixture was concentrated in vacuo, diluted
with ice-cold water (20–25 ml) and acidified with 2 N
HCl. The suspension was extracted with CH2Cl2
(3 ¥ 25 ml), and removal of the solvent resulted in com-
pounds 5a-c, which were purified by crystallization in
ethanol.
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Fig. 3. Synthesis of pyridazine-based analogs 15a,b and 18.
Reagents and conditions: (A) 4-methoxyphenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), Et3N (2 equiv), CH2Cl2, 12 h, rt; (B) NH3/anhydrous
EtOH, 7 h, 180°C; (C) for 15a: 4-bromophenylisocyanate (1.1 equiv) anhydrous toluene, 6 h, reflux; for 15b: 4-bromobenzoyl chloride (4 equiv),
Et3N (catalytic), anhydrous CH2Cl2, 24 h, 0°C/rt; (D) ethyl bromoacetate (3 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 8 h, reflux; (E) NaOH
6 N, 2 h, 80°C; (F) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-bromoaniline (2 equiv), anhydrous THF, 12 h, -5°C/rt.
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6-Methyl-4-[4-(methylthio)benzyl]pyridazin-3(2H)-
one (5a)
Mp = 151–153°C; crystallization solvent = EtOH;
yield = 46%. 1H NMR (CDCl3), d: 2.26 (3H, s), 2.51
(3H, s), 3.87 (2H, s), 6.71 (1H, s), 7.18 (2H, d,
J = 8.2 Hz), 7.27 (3H, dd, J = 9.3, 1.8 Hz).
General procedure for compounds (6a,b)
A mixture of the suitable intermediate 5a,b
(4.50 mmol), K2CO3 (9.00 mmol), and ethyl bromoac-
etate (6.75 mmol) in CH3CN (10 ml) was refluxed
under stirring for 2–4 h. The mixture was then concen-
trated in vacuo, diluted with cold water, and extracted
with CH2Cl2 (3 ¥ 15 ml). The solvent was evaporated in
vacuo, and compounds 6a and b were purified by crys-
tallization from ethanol.
Ethyl-2-{3-methyl-5-[4-(methylthio)benzyl]-6-
oxopyridazin-1(6H)-yl}acetate (6a)
Mp = 129–131°C; crystallization solvent = EtOH;
yield = 99.9%. 1H NMR (CDCl3), d: 1.31 (3H, t, J =
6.8 Hz), 2.24 (3H, s), 2.51 (3H, s), 3.87 (2H, s), 4.27
(2H, q, J = 6.8 Hz), 4.86 (2H, s), 6.68 (1H, s), 7.17 (2H,
d, J = 7.3 Hz), 7.25–7.29 (2H, m).
General procedure for compounds (7a,b)
A suspension of the intermediate 6a and 6b
(4.40 mmol) in 6 N NaOH (10 ml) was stirred at 80°C
for 1–2 h. The mixture was first diluted with ice-cold
water and then acidified with 6 N HCl. Products 7a
and 7b were filtered by suction and recrystallized from
ethanol.
2-{3-Methyl-5-[4-(methylthio)benzyl]-6-
oxopyridazin-1(6H)-yl}acetic acid (7a)
Mp = 87–89°C; crystallization solvent = EtOH;
yield = 99.9%. 1H NMR (CDCl3), d 2.25 (3H, s), 2.51
(3H, s), 3.87 (2H, s), 4.91 (2H, s), 6.69 (1H, s), 7.16 (2H,
d, J = 7.6 Hz), 7.25 (2H, d, J = 7.6 Hz).
General procedure for compounds (1) [Cilibrizzi
et al., 2009] and (8a-c)
To a cooled (-5°C) and stirred solution of the
appropriate carboxylic acid 7a,b (0.90 mmol), in anhy-
drous tetrahydrofuran (6 ml), Et3N (3.15 mmol) was
added. After 30 min, the mixture was allowed to warm
up to 0°C, and ethyl chloroformate (0.99 mmol) was
added. After 1 h, the appropriately substituted ary-
lamine (1.80 mmol) was added, and the reaction was
carried out at room temperature (rt) for 12 h. The
mixture was then concentrated in vacuo, diluted with
cold water (10–15 ml) and extracted with CH2Cl2
(3 ¥ 15 ml). The solvent was evaporated to obtain final
compounds 1 and 8a-c, which were purified by column
chromatography using cyclohexane/ethyl acetate 1:1 for
compounds 1 and 8a,c and cyclohexane/ethyl acetate
2:1 for 8b as eluents.
N-(4-Bromophenyl)-2-{3-methyl-5-[4-(methylthio)
benzyl]-6-oxo-pyridazin-1(6H)-yl}acetamide (8a)
Mp = 97–99°C; purified by column chromatogra-
phy (cyclohexane/ethyl acetate 1:1); yield = 10%. 1H
NMR (CDCl3) d 2.30 (3H, s), 2.50 (3H, s), 3.89 (2H, s),
4.94 (2H, s), 6.80 (1H, s), 7.17 (2H, d, J = 8.2 Hz), 7.24
(2H, d, J = 8.2 Hz), 7.39 (4H, dd, J = 2.6, 5.7 Hz), 9.01
(1H, exch br s). MS (ESI) Calcd. for C21H20BrN3O2S,
458.37. Found: m/z 458.17 [M + H]+. Anal. Calcd for
C21H20BrN3O2S: C, 55.03; H, 4.40; N, 9.17. Found: C,
54.92; H, 4.39; N, 9.20.
N-(4-Iodophenyl)-2-{3-methyl-5-[4-(methylthio)
benzyl]-6-oxo-pyridazin-1(6H)-yl}acetamide (8b)
Mp = 68–70°C; purified by column chromatogra-
phy (cyclohexane/ethyl acetate 2:1); yield = 46%. 1H
NMR (CDCl3) d 2.30 (3H, s), 2.51 (3H, s), 3.89 (2H, s),
4.93 (2H, s), 6.80 (1H, s), 7.18 (2H, s, J = 8.4 Hz), 7.24-
7.28 (4H, m), 7.61 (2H, d, J = 8.8 Hz), 8.92 (1H, exch br
s). MS (ESI) Calcd. for C21H20IN3O2S, 505.37. Found:
m/z 506.11 [M + H]+. Anal. Calcd for C21H20IN3O2S:
C, 49.91; H, 3.99; N, 8.31. Found: C, 49.86; H, 4.01;
N, 8.34.
2-[5-(3-Methoxybenzyl)-3-methyl-6-oxopyridazin-1
(6H)-yl]-N-[4-(methylthio)phenyl]acetamide (8c)
Mp = 166–167°C; purified by column chromatog-
raphy (cyclohexane/ethyl acetate 1:1); yield = 99.9%. 1H
NMR (CDCl3), d 2.28 (3H, s), 2.45 (3H, s), 3.80 (3H, s),
3.89 (2H, s), 4.95 (2H, s), 6.79–6.85 (4H, m), 7.12–
7.15 (1H, m), 7.27 (1H, t, J = 7.8 Hz), 7.39 (2H, d,
J = 5.0 Hz), 9.13 (1H, exch br s). MS (ESI) Calcd. for
C22H23N3O3S, 409.50. Found: m/z 410.11 [M + H]+.
Anal. Calcd for C22H23N3O3S: C, 64.53; H, 5.66; N,
10.26. Found: C, 64.66; H, 5.64; N, 10.22.
N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-
3-methyl-6-oxo-pyridazin-1(6H)-
yl]ethanethioamide (9)
Compound 9 was obtained by slow addition of
Lawesson’s reagent (0.28 mmol) to a stirred solution of
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compound 1 (0.14 mmol) in toluene (3 ml), and the
reaction was carried out at reflux for 3 h. The solvent
was removed in vacuo, and the mixture was diluted with
ice-cold water and extracted with CH2Cl2 (3 ¥ 10 ml).
The crude product was finally purified by flash column
chromatography using cyclohexane/ethyl acetate 1:1 as
eluent, to yield 9 as an amorphous solid. Mp = 68–
70°C; crystallization solvent = EtOH; yield = 30%. 1H
NMR (CDCl3), d 2.32 (3H, s), 3.81 (3H, s), 3.92 (2H, s),
5.37 (2H, s), 6.81 (1H, s), 6.83-6.87 (3H, m), 7.28 (1H,
t, J = 5.0 Hz), 7.48 (2H, d, J = 8.8 Hz), 7.74 (2H, d,
J = 8.8 Hz), 11.46 (1H, exch br s). MS (ESI) Calcd. for
C21H20BrN3O2S, 458.37. Found: m/z 458.17 [M + H]+,
482.36 [M + Na]+, 378.45 [M – Br]+, 231.17 [M –
C8H7BrNS]+. Anal. Calcd for C21H20BrN3O2S: C, 55.03;
H, 4.40; N, 9.17. Found: C, 55.08; H, 4.39; N, 9.19.
4-(4-Methoxybenzyl)-6-methylpyridazine-3(2H)-
thione (10)
Lawesson’s reagent (0.87 mmol) was slowly added
to a stirred solution of intermediate 5c (0.87 mmol) in
toluene (3 ml), and the reaction was carried out at reflux
for 2 h. The mixture was cooled and after 1 h stirring
in ice-bath, the precipitate was filtered and purified
by recrystallization from ethanol. Mp = 191–193°C;
crystallization solvent = EtOH; yield = 47%. 1H NMR
(CDCl3), d 2.30 (3H, s), 3.85 (3H, s), 4.11 (2H, s), 6.57
(1H, s), 6.93 (2H, d, J = 8.5 Hz), 7.17 (2H, d,
J = 8.5 Hz), 12.12 (1H, exch br s).
N-(4-Bromophenyl)-2-[4-(4-methoxybenzyl)-6-
methylpyridazin-3-ylthio]acetamide (11)
A mixture of compound 10 (0.41 mmol), K2CO3
(0.82 mmol), and N-(4-bromophenyl)-2-chloro aceta-
mide (0.61 mmol) in CH3CN (4 ml) was refluxed under
stirring for 1.5 h. After cooling, the solvent was evapo-
rated, and the mixture was diluted with cold water. The
precipitate was filtered and purified by flash chroma-
tography using cyclohexane/ethyl acetate 1:2 as eluent.
Mp = 116–118°C; purified by column chromatography
(cyclohexane/ethyl acetate 1:2); yield = 96%. 1H NMR
(CDCl3), d 2.62 (3H, s), 3.84 (3H, s), 3.87 (2H, s), 4.08
(2H, s), 6.84 (1H, s), 6.92 (2H, d, J = 8.5 Hz), 7.11 (2H,
d, J = 8.5 Hz), 7.38 (2H, d, J = 8.8 Hz), 7.48 (2H, d,
J = 8.8 Hz), 10.26 (1H, exch br s). MS (ESI) Calcd. for
C21H20BrN3O2S, 458.37. Found: m/z 458.11 [M + H]+.
Anal. Calcd for C21H20BrN3O2S: C, 55.03; H, 4.40; N,
9.17. Found: C, 54.81; H, 4.38; N, 9.19.
3-Chloro-4-(4-methoxyphenoxy)-6-
phenylpyridazine (13)
A suspension of 3-chloro-6-phenylpyridazin-
4-ol 12 (1.31 mmol), 4-methoxyphenylboronic acid
(2.62 mmol), copper acetate (1.96 mmol), and Et3N
(2.62 mmol) in CH2Cl2 (10 ml) was stirred for 12 h at rt.
The copper salts were filtered off, and the organic
layer was extracted with 50% aqueous ammonia
(3 ¥ 10 ml), washed with water (10 ml), and dried over
Na2SO4. After removal of the solvent in vacuo, the
residue was purified by flash column chromato-
graphy using cyclohexane/ethyl acetate 1:1 as eluent.
Mp = 124–126°C; purified by column chromatography
(cyclohexane/ethyl acetate 1:1); yield = 48%. 1H-NMR
(CDCl3), d: 3.86 (3H, s), 6.99 (2H, d, J = 9.2 Hz), 7.45-
7.47 (3H, m), 7.61 (2H, d, J = 9.2 Hz), 7.78-7.80 (2H,
m), 7.93 (s, 1H).
4-(4-Methoxyphenoxy)-6-phenylpyridazin-3-
amine (14)
A solution of compound 13 in saturated ethanolic
ammonia was heated in a sealed stainless steel tube
at 180°C for 7 h. The mixture was then concen-
trated in vacuo, and the residue was treated with cold
diethyl ether to obtain a crude solid that was recovered
by suction and recrystallized by ethanol. Mp = 160–
162°C; crystallization solvent = EtOH; yield = 99.9%.
1H-NMR (DMSO), d: 3.79 (3H, s), 6.66 (2H, exch br s),
6.78 (1H, s), 7.01 (2H, d, J = 8.4 Hz), 7.38-7.43 (3H, m),
7.53 (2H, d, J = 8.4 Hz), 7.73 (2H, d, J = 7.2 Hz).
1-(4-Bromophenyl)-3-[4-(4-methoxyphenoxy)-6-
phenylpyridazin-3-yl]urea (15a)
To a stirred solution of compound 14 (0.23 mmol)
in anhydrous toluene (3 ml), 4-bromophenyl isocyanate
(0.26 mmol) was added. The mixture was refluxed for
6 h. After cooling, the solvent was removed under
reduced pressure, and the residue was dissolved in
CH2Cl2 and washed, in turn, with 2 N HCl (3 ¥ 15 ml),
2 N NaOH (3 ¥ 15 ml), and with H2O (15 ml). The
organic layer was dried over Na2SO4 and evaporated in
vacuo to obtain the crude products, which were purified
by flash column chromatography using CH2Cl2/CH3OH
(gradient 100:0 to 98:2) as eluent. Mp = 267–269°C;
purified by column chromatography (CH2Cl2/CH3OH,
gradient 100:0 to 98:2); yield = 25%. 1H-NMR (CDCl3),
d: 3.65 (3H, s), 6.82 (4H, d, J = 8.8 Hz), 7.42–7.48 (5H,
m), 7.64 (2H, d, J = 8.8 Hz), 7.89–7.92 (2H, m), 8.55
(1H, exch br s), 8.80 (1H, s), 9.42 (1H, exch br s). MS
(ESI) Calcd. for C24H19BrN4O3, 491.34. Found: m/z
491.11 [M + H]+. Anal. Calcd for C24H19BrN4O3: C,
58.67; H, 3.90; N, 11.40. Found: C, 58.55; H, 3.89;
N, 11.35.
4-Bromo-N-[4-(4-methoxyphenoxy)-6-
phenylpyridazin-3-yl]benzamide (15b)
Et3N (0.025 ml) and 4-bromobenzoyl chloride
(0.67 mmol) were added to a cooled (0°C) and stirred
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solution of 14 (0.33 mmol) in anhydrous CH2Cl2 (4 ml),
and the reaction was mantained under stirring at
0°C for 3 h. Additional 4-bromobenzoyl chloride
(0.67 mmol) was added, and the mixture was stirred at
rt for 24 h. The solid residue was removed by filtration,
and the organic layer was washed with 6 N NaOH
(3 ¥ 10 ml), 6 N HCl (3 ¥ 10 ml) and, finally, with cold
water (2 ¥ 10 ml). Drying with Na2SO4 and evaporation
of the solvent in vacuo resulted in crude compound
15b, which was purified by flash chromatography
using CH2Cl2 as eluent. Mp = 203–204°C; purified
by column chromatography (CH2Cl2); yield = 63%.
1H-NMR (CDCl3), d: 3.87 (3H, s), 7.02 (2H, d,
J = 8.4 Hz), 7.44–7.49 (3H, m), 7.66 (4H, t, J = 8.4 Hz),
7.83 (2H, s. J = 8.4 Hz), 7.91 (2H, dd, J = 6.0, 2.0 Hz),
8.84 (1H, s), 9.52 (1H, exch br s). MS (ESI) Calcd. for
C24H18BrN3O3, 476.32. Found: m/z 476.11 [M + H]+.
Anal. Calcd for C24H18BrN3O3: C, 60.52; H, 3.81; N,
8.82. Found: C, 60.46; H, 3.82; N, 8.85.
Ethyl 2-[4-(4-methoxyphenoxy)-6-phenylpyridazin-
3-ylamino]acetate (16)
A mixture of the intermediate 14 (0.33 mmol),
K2CO3 (0.66 mmol), and ethyl bromoacetate (1.00
mmol) in CH3CN (4 ml) was refluxed with stirring for
8 h. The mixture was then concentrated, diluted with
cold water, and extracted with CH2Cl2 (3 ¥ 15 ml). The
organic layer was dried over Na2SO4 and evaporated
in vacuo to obtain the crude product 16, which was
purified by flash chromatography using cyclohexane/
ethyl acetate 2:1 as eluent. Mp = 130–132°C; purified
by column chromatography (cyclohexane/ethyl acetate
2:1); yield = 79%. 1H NMR (CDCl3), d: 1.32 (3H, t,
J = 7.2 Hz), 3.83 (3H, s), 4.04 (2H, d, J = 5.2 Hz), 4.26
(2H, q, J = 7.2 Hz), 6.39 (1H, s), 6.98 (2H, d, J = 8.8 Hz),
7.39-7.43 (3H, m), 7.62 (2H, d, J = 8.8 Hz), 7.78 (2H, d,
J = 7.6 Hz).
2-[4-(4-Methoxyphenoxy)-6-phenylpyridazin-3-
ylamino]acetic acid (17)
A suspension of compound 16 (0.30 mmol) in 6 N
NaOH (4 ml) was stirred at rt to 80°C for 2 h. The
mixture was first diluted with ice-cold water, acidified
with 6 N HCl, and then extracted with CH2Cl2. The
organic layer was dried over Na2SO4 and evaporated in
vacuo to obtain the crude product 17, which was puri-
fied by recrystallization from ethanol. Mp = 203–205°C;
crystallization solvent = EtOH; yield = 54%. 1H NMR
(CDCl3), d: 3.83 (3H, s), 3.95 (2H, s), 6.42 (1H, s),
6.94–6.97 (2H, m), 7.40–7.48 (3H, m), 7.57 (2H, d,
J = 8.8 Hz), 7.76–7.79 (2H, m).
N-(4-Bromophenyl)-2-[4-(4-methoxyphenoxy)-6-
phenylpyridazin-3-ylamino]acetamide (18)
To a cooled (-5°C) and stirred solution of the
carboxylic acid 17 (0.14 mmol) in anhydrous tetrahy-
drofuran (5 ml), Et3N (0.49 mmol) was added. After
30 min, the mixture was allowed to warm up to 0°C, and
ethyl chloroformate (0.15 mmol) was added. After 1 h,
4-bromoaniline (0.28 mmol) was added. The reaction
was carried out at room temperature for 5 h. The
mixture was then concentrated in vacuo, diluted with
cold water (10–15 ml), and extracted with CH2Cl2
(3 ¥ 15 ml). The solvent was evaporated to obtain final
compound 18, which was purified by column chroma-
tography using cyclohexane/ethyl acetate 1:1 as eluent.
Mp = 238–239°C; purified by column chromatography
(cyclohexane/ethyl acetate 1:1); yield = 28%. 1H-NMR
(CDCl3), d: 3.83 (3H, s), 4.09 (2H, s), 6.60 (1H, s),
6.96 (2H, d, J = 9.2 Hz), 7.41-7.49 (7H, m), 7.58 (2H,
d, J = 9.2 Hz), 7.76 (2H, dd, J = 5.2, 2.8 Hz), 8.25 (1H,
exch br s). MS (ESI) Calcd. for C25H21BrN4O3,
505.36. Found: m/z 505.10 [M + H]+. Anal. Calcd for
C25H21BrN4O3: C, 59.42; H, 4.19; N, 11.09. Found: C,
59.53; H, 4.17; N, 11.11.
Pharmacology
Cell culture
Human promyelocytic leukemia HL-60 cells
stably transfected with FPR1 (HL-60-FPR1), FPR2
(HL-60-FPR2), or FPR3 (HL-60-FPR3) were cultured
in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum, 10 mMHEPES, 100 mg/ml
streptomycin, 100 U/ml penicillin, and G418 (1 mg/ml),
as previously described [Christophe et al., 2002]. Wild-
type HL-60 cells were cultured under the same condi-
tions but without G418.
Isolation of human neutrophils
Blood was collected from healthy donors in accor-
dance with a protocol approved by the Institutional
Review Board at Montana State University. Neutro-
phils were purified from the blood using dextran
sedimentation, followed by Histopaque 1077 (Sigma
Aldrich, St. Louis, MO USA) gradient separation and
hypotonic lysis of red blood cells, as previously
described [Schepetkin et al., 2007]. Isolated neutro-
phils were washed twice and resuspended in HBSS
without Ca2+ and Mg2+ (Hank’s balanced salt solution
[HBSS-]; Mediatech, Inc., Herndon, VA). Neutrophil
preparations were routinely >95% pure, as determined
by light microscopy, and >98% viable, as determined by
trypan blue exclusion.
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Ca2+ mobilization assay
Changes in intracellular Ca2+ were measured with
a FlexStation II scanning fluorometer using a FLIPR 3
calcium assay kit (Molecular Devices, Sunnyvale, CA)
for human neutrophils and HL-60 cells. All active com-
pounds were evaluated in parent (wild-type) HL-60
cells to verify that agonists are inactive in nontrans-
fected cells (data not shown). Human neutrophils or
HL-60 cells, suspended in HBSS- containing 10 mM
HEPES, were loaded with Fluo-4 AM dye (Invitrogen,
Eugene, OR) (1.25 mg/ml final concentration) and incu-
bated for 30 min in the dark at 37°C. After dye loading,
the cells were washed with HBSS- containing 10 mM
HEPES, resuspended in HBSS containing 10 mM
HEPES and Ca2+ and Mg2+ (HBSS+), and aliquotted
into the wells of a flat-bottomed, half-area-well black
microtiter plates (2 ¥ 105 cells/well). The compound
source plate contained dilutions of test compounds in
HBSS+. Changes in fluorescence were monitored
(lex = 485 nm, lem = 538 nm) every 5 s for 240 s at room
temperature after automated addition of compounds.
Maximum change in fluorescence, expressed in arbi-
trary units over baseline, was used to determine agonist
response. Responses were normalized to the response
induced by 5 nM fMLF (Sigma Chemical Co., St.
Louis, MO) for HL-60-FPR1 and neutrophils, or 5 nM
Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) (Cal-
biochem, San Diego, CA) for HL-60-FPR2 and HL-60-
FPR3 cells, which were assigned a value of 100%.
Curve fitting (5–6 points) and calculation of EC50 were
performed by nonlinear regression analysis of the dose–
response curves generated using Prism 5 (GraphPad
Software, Inc., San Diego, CA).
Chemotaxis assay
Neutrophils were suspended in HBSS+ containing
2% (v/v) fetal bovine serum (FBS) (2 ¥ 106 cells/ml),
and chemotaxis was analyzed in 96-well ChemoTx
chemotaxis chambers (Neuroprobe, Gaithersburg,
MD), as previously described [Schepetkin et al., 2007].
In brief, lower wells were loaded with 30 ml of HBSS+
containing 2% (v/v) FBS and the indicated concentra-
tions of test compound, DMSO (negative control), and
1 nM fMLE as a positive control. The number of
migrated cells was determined by measuring ATP in
lysates of transmigrated cells using a luminescence-
based assay (CellTiter-Glo; Promega, Madison, WI),
and luminescence measurements were converted to
absolute cell numbers by comparison of the values
with standard curves obtained with known numbers of
neutrophils. The results are expressed as percentage
of negative control and were calculated as follows:
(number of cells migrating in response to test
compounds/spontaneous cell migration in response to
control medium) ¥ 100. EC50 values were determined
by nonlinear regression analysis of the dose–response
curves generated using Prism 5 software.
Molecular modeling
The FPR1 homology model was created using the
crystal structure of bovine rhodopsin, as reported pre-
viously [Movitz et al., 2010]. A Protein Data Bank
(PDB) file of the homology model was loaded into the
Molegro Virtual Docker (MVD) program (MVD
2010.4.2, Molegro ApS, Katrinebjerg, Denmark). The
position of the ligand binding site in the model was
recently localized by docking studies of different FPR1
agonists [Movitz et al., 2010; Khlebnikov et al., 2012].
Docking search space was defined as a sphere centered
at the carbonyl carbon of the Ala residue in the FPR1
peptide agonist Ac-QAWF in its docking pose obtained
by Movitz et al. [2010]. The radius of the sphere was
adopted to be equal to 11 Å. This search space encom-
passed the whole Ac-QAWF molecule and included, at
least partially, 36 residues of FPR1. Among these, side
chains of 23 residues closest to the center of the search
space were set flexible during the docking simulation.
For FPR2 homology modeling, the primary amino
acid sequence of FPR2 was submitted to the Phyre2
(Protein Homology/analogy Recognition Engine V2.0)
protein fold recognition server (Structural Bioinformat-
ics Group, Imperial College, London; http://www.sbg.
bio.ic.ac.uk/phyre2) [Kelley and Sternberg, 2009], and
the homology model, created using the crystal structure
of bovine rhodopsin, was optimized, as described
recently [Schepetkin et al., 2013].
Taking into account a lack of structural informa-
tion about any ligand-receptor complex with FPR2, we
tried to locate cavities in the macromolecule obtained
by homology modeling in order to identify the search
space for docking. Use of the MVD “Detect cavity”
module with probe size 1.2 Å gave two cavities with
volumes of 241 and 25 Å3 in the region of the binding
site. Positions of these two cavities reflect an asymmet-
ric dumb-bell shape of the binding site. Hence, for
FPR2, we also chose a spherical search space with a
default radius 15 Å centered at the terminus of the
larger cavity directed to the smaller one. This sphere
embraced two cavities and eight residues reported by
Fujita et al. [Fujita et al., 2011]. Side chains of 45 resi-
dues closest to the center of the sphere were considered
flexible in the docking study.
Before docking, structures of the compounds
were preoptimized using HyperChem software (Hyper-
cube, Inc., Gainesville, FL) with MM+ force field and
saved in Tripos MOL2 format. The ligand structures
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were then imported into the MVD program with the
following options enabled: “Create explicit hydrogens,”
“Assign charges (calculated by MVD),” and “Detect
flexible torsions in ligands.” Selected molecules were
docked into FPR1 and FPR2 using the search spaces
indicated above with a rigid receptor structure. Ligand
flexibility was accounted for with respect to torsion
angles autodetected in MVD. MolDock score functions
were used with 0.3 Å grid resolution. The “Internal
H-bond” option was activated in the “Ligand evalua-
tion” menu of Docking Wizard. Fifteen docking runs
were performed for each molecule with side chain flex-
ibility enabled for the residues mentioned above. The
postprocessing options “Energy minimization” and
“Optimize H-bonds” were applied after docking.
RESULTS AND DISCUSSION
We synthesized a series of new pyridazin-3(2H)-
one-based thioderivatives and pyridazine analogs and
screened them in order to identify novel molecules able
to activate human neutrophils through FPRs. The final
compounds were evaluated for their ability to induce
intracellular Ca2+ flux in HL-60 cells transfected with
FPR1, FPR2, or FPR3, as it is possible to estimate FPR
binding using this assay system [Prossnitz et al., 1991;
Didsbury et al., 1992]. Both EC50 values and relative
efficacy, compared with the peptide agonists (fMLF
and WKYMVm) and previously described pyrida-
zinones 1–3 (Fig. 1 and [Cilibrizzi et al., 2009]), were
determined. All compounds were also evaluated in
wild-type, nontransfected HL-60 cells to verify re-
sponse specificity. Moreover, the compounds that
showed the best profile were selected to evaluate their
chemotactic activity and capacity to mobilize Ca2+ in
human neutrophils.
Analysis of pyridazinone derivatives containing a
methylthio group in the phenyl ring at position C-4
(Table 1) showed that substitution of OCH3 at this posi-
tion of the previously published FPR2-specific agonist 2
(Fig. 1 and [Cilibrizzi et al., 2009]) with SCH3 resulted
in compound 8a, which was inactive for all FPRs. Thus,
differences in steric hindrance between oxygen and
sulfur appear to result in loss of agonist activity. Sur-
prisingly, the iodine analog, compound 8b, had agonist
activity in the micromolar range for both FPR1 and
FPR2. Similarly, substitution of OCH3 in the para posi-
tion of the phenylacetamide linker of reference com-
pound 3 (Fig. 1 and [Cilibrizzi et al., 2009]) with SCH3
(compound 8c) did not change FPR agonist activity,
keeping the potency at micromolar levels. These data
suggest that it is possible to modify the para position of
phenylacetamide side chain, resulting in compounds
with similar activity. In contrast, transformation of our
lead compound 1 (Fig. 1 and [Cilibrizzi et al., 2009]) by
substitution of the oxygen atom in the amide bridge
TABLE 1. Functional Activity of New Pyridazin-3(2H)-One Thioderivatives 8a-c and 9 in HL-60 Cells Expressing Human FPR1, FPR2, or
FPR3, in Comparison with Reference Compounds 1–3*
N
N
X
NH
R1
O
R
Compd. R X R1
Ca2+ mobilization EC50 (mM) and efficacy (%)†
FPR1 FPR2 FPR3
1* OCH3 (m) O Br 3.4  1.6 (75) 3.8  1.5 (70) N.A.
9 OCH3 (m) S Br N.A. N.A. N.A.
2* OCH3 (p) O Br N.A. 2.4  0.9 (70) N.A.
8a SCH3 (p) O Br N.A. N.A. N.A.
3* OCH3 (m) O OCH3 7.7  2.5 (65) 14.4  2.0 (35) N.A.
8c OCH3 (m) O SCH3 2.2  0.69 (70) 8.2  2.5 (40) N.A.
8b SCH3 (p) O I 2.3  0.72 (80) 9.4  2.7 (60) N.A.
fMLF 0.01 20.4 1.9
WKYMVm 0.5 0.001 0.01
*Values of activity and efficacy are from Cilibrizzi et al. [2009].
†N.A., no activity was observed (no response was observed during first 2 min after addition of compounds under investigation) considering the
limits of efficacy >20% and EC50 <50 mM. EC50 values are presented as the mean  standard deviation of three independent experiments, in
which median effective concentration values (EC50) were determined by nonlinear regression analysis of the dose–response curves (5–6 points)
generated using GraphPad Prism 5 with 95% confidential interval (P < 0.05). Efficacy (in parentheses) is expressed as % of the response induced
by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).
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with a sulfur atom led to thioamide 9, which was inac-
tive. Lastly, none of the pyridazine analogs (11, 15a,b,
and 18) exhibited FPR agonist activity.
Both FPR1/FPR2 agonists 8b and 8c activated
human neutrophil Ca2+ flux (EC50 = 2.2 and 2.1 mM,
respectively) and chemotaxis (EC50 = 2.9 and 2.4 mM,
respectively). Representative dose–response curves for
these activities are shown in Figure 4.
Molecular docking of selected thioderivatives into
the FPR1 and FPR2 binding sites was performed to
assess how the presence of the sulfur atom might influ-
ence the binding modes of the compounds as compared
with their oxygen-containing analogs. Taking into
account that FPR1 has a more open and broader
binding site than FPR2, the docking results were ana-
lyzed in terms of partial interactions of ligands with
FPR1 residues. As shown in Figure 5, compounds 8a,
8b, 1, and 9 occupy different locations within the
receptor. Arg205 is one of the key residues contributing
to FPR1 agonist activity [Mills et al., 2000; Khlebnikov
et al., 2012], and the highly active peptide fMLE and
2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived
FPR1 agonists strongly interacted with Agr205, includ-
ing formation of H-bonds [Khlebnikov et al., 2012].
Likewise, our docking studies indicated that compound
8b had interaction energy of -20.02 kcal/mol with
Arg205 and was H-bonded to this residue, whereas the
A
B
Fig. 4. Activation of human neutrophils by selected compounds. (A)
Representative kinetics of neutrophil intracellular Ca2+ flux after treat-
ment with compound 8b or fMLF. Human neutrophils were treated
with different concentrations of the compound 8b, 5 nM fMLF, or 1%
DMSO (negative control), and Ca2+ flux was monitored for the indi-
cated times. The data are from one experiment that is representative of
three independent experiments. (B) Human neutrophil chemotaxis
toward the indicated concentrations of compounds 8b () and 8c ()
was determined, as described under Materials and Methods. The
data are presented as the mean  standard deviation of duplicate
samples from one experiment that is representative of two indepen-
dent experiments.
Fig. 5. Docking poses of selected pyridazine derivatives within the
FPR1 binding site. (A) Poses of active compound 8b (blue) and inactive
compound 8a (brown). (B) Poses of active compound 1 (yellow) and
inactive compound 9 (sage). [Color figure can be viewed in the online
issue which is available at wileyonlinelibrary.com]
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inactive derivative 8a had a very weak, nonbonded
attraction to Arg205. Additionally, molecule 8b formed
H-bonds with Thr265, whereas 8a was not H-bonded
to any FPR1 residue (Fig. 5A). A similar situation
occurred for the active and inactive compounds 1 and
9, respectively (Fig. 5B). Active pyridazine 1 formed an
H-bond with Arg205 and had total interaction energy of
32.9 kcal/mol with this residue. On the other hand,
compound 9 had a much weaker, nonbonded interac-
tion with Arg205 (-8.82 kcal/mol).
Pairs of sulfur- and oxygen-containing compounds
were also compared for their ability to interact with
FPR2. As an example, a detailed comparison of docking
poses for the active oxygen-containing compound 2 and
its inactive methylthio analog 8a showed that com-
pound 8a did not have any satisfactory binding mode
within the FPR2 binding site and that its best docking
pose had significant repulsive interactions with Tyr277
and Ile280 of FPR2. These steric conflicts made it
impossible for the sulfur-containing ligand to effectively
penetrate into the receptor cavity. In spite of H-
bonding with Asn171 and Asp173, this docking pose
was energetically unfavorable, and its MolDock score
was about 76 kcal/mol higher than that of the active
methoxy-derivative 2. In comparison, the best pose of
agonist 2 was well incorporated into the cavity of the
241 Å3 binding site obtained with the MVD “Detect
Cavity” feature (see Materials and Methods). The
closest nonvalent contact of 2.48 Å occurred between
the oxygen atom of the ligand 2 methoxy group and
Thr168. An analogous pose would be impossible for
compound 8awhose methylthio group is far more bulky
than the methoxy substituent in molecule 2.
The docking poses of active oxygen-containing
derivatives 1–3 and 8c fit the FPR2 cavity well
(Fig. 6A). In contrast, the inactive sulfur-containing
pyridazine derivatives 8a and 9 had molecular frag-
ments outside the cavity, which caused steric hin-
drances and prevented an effective binding of the
ligands with FPR2 (Fig. 6B). Such positions of com-
pounds 8a and 9 within the binding site were restricted
by the bulkiness of sulfur-containing molecular frag-
ments. Hence, these molecules cannot adopt more
suitable conformations that are possible for the corre-
sponding oxygen-containing derivatives.
Overall, our docking studies showed that binding
modes of oxygen-containing pyridazine derivatives are
quite different from their thio-analogs. In the case of
FPR2, this is caused mainly by bulkiness of sulfur-
containing groups, i.e. by a higher van der Waals radius
and longer valence bonds formed by sulfur atoms with
respect to oxygen atoms. It is also known that sulfur
forms much weaker H-bonds than oxygen [Wood et al.,
2008]. Although the importance of H-bonds for binding
to a receptor was shown here for some active FPR1 and
FPR2 agonists, the docking studies indicated that
replacement of the sulfur atom by oxygen did not lead
to emergence of an H-bond with participation of this
oxygen atom in docking. We also confirmed that most
active FPR1 agonists strongly interact with Arg205 of
the receptor, as described previously [Mills et al., 2000;
Khlebnikov et al., 2012].
In conclusion, we synthesized several novel FPR
agonists with pyridazinone or pyridazine scaffolds as
modified analogs of the previously reported series
of FPR agonists [Cilibrizzi et al., 2009]. Among the
pyridazinone analogs tested, thioderivatives 8b and 8c
were mixed FPR1/FPR2 agonists with micromolar
activity, whereas all pyridazine analogs and thioderiva-
tives 8a and 9 were completely inactive. Furthermore,
Fig. 6. Docking poses of selected pyridazine derivatives within the
FPR2 binding site. The cavity of FPR2 found by the MVD program is
shown by a green grid, and residues closest to the cavity are shown.
(A) Poses of active compounds 1 (yellow), 2 (light-blue), 3 (green), and
8c (blue) fit the receptor cavity well. (B) Poses of inactive compounds
8a (magenta) and 9 (red) have molecular fragments outside of the
cavity (p-bromophenyl groups of compounds 8a and 9; methyl and
methythio groups of compound 8a). [Color figure can be viewed in the
online issue which is available at wileyonlinelibrary.com]
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molecular docking studies suggested that the inactivity
of these thioderivatives was due to a weak H-bonding
acceptor and bulkiness of sulfur-containing molecular
fragments. These findings confirmed the crucial impor-
tance of the pyridazinone scaffold for the activity of this
class of compounds.
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